Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma
NCT04097028 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22
Last updated 2025-04-29
Summary
This phase II trial studies how well trifluridine/tipiracil and oxaliplatin work as the first line of treatment (induction) in treating patients with esophageal or gastroesophageal junction adenocarcinoma that can be removed by surgery (resectable). Drugs used in chemotherapy, such as trifluridine/tipiracil and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Conditions
- Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8
- Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8
- Clinical Stage III Esophageal Adenocarcinoma AJCC v8
- Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
- Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8
- Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
- Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8
- Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8
- Pathologic Stage III Esophageal Adenocarcinoma AJCC v8
- Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
- Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8
- Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8
- Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8
- Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8
- Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8
- Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
Interventions
- DRUG
-
Trifluridine and Tipiracil Hydrochloride
Given PO
- DRUG
-
Given IV
Sponsors & Collaborators
-
National Comprehensive Cancer Network
collaborator NETWORK -
Roswell Park Cancer Institute
lead OTHER
Principal Investigators
-
Christos Fountilas, MD · Roswell Park Cancer Institute
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-12-20
- Primary Completion
- 2022-12-16
- Completion
- 2025-02-05
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
NCT04891289 ·Status: RECRUITING ·Phase: PHASE2
-
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
NCT04491942 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers
NCT00678132 ·Status: COMPLETED ·Phase: PHASE1
-
Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00016367 ·Status: COMPLETED ·Phase: PHASE2
-
PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies
NCT01522989 ·Status: UNKNOWN ·Phase: PHASE1
-
Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies
NCT00251407 ·Status: COMPLETED ·Phase: PHASE1
-
Surgery, Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Non-Small Cell Lung Cancer
NCT00530634 ·Status: TERMINATED ·Phase: PHASE2
-
Edotecarin and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors
NCT00072332 ·Status: COMPLETED ·Phase: PHASE1
-
Oxaliplatin in Esophagus Cancer (Advanced) 1st Line
NCT00259402 ·Status: COMPLETED ·Phase: PHASE2
-
Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors
NCT00074321 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
NCT00004242 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Trial of XP Versus XG in Advanced Esophageal Squamous Cell Carcinoma
NCT01474642 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II (Treatment) Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies
NCT00266279 ·Status: COMPLETED ·Phase: PHASE2
-
Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction
NCT00062374 ·Status: COMPLETED ·Phase: PHASE2
-
Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma
NCT00667420 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer
NCT03579771 ·Status: COMPLETED ·Phase: PHASE2
-
Combination of Capecitabine and Oxaliplatin in Metastatic Nasopharyngeal Carcinoma
NCT00363831 ·Status: UNKNOWN ·Phase: PHASE2
-
Oxaliplatin to Treat Advanced Cancers With Liver Dysfunction
NCT00006062 ·Status: COMPLETED ·Phase: PHASE1
-
Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer
NCT01338792 ·Status: COMPLETED ·Phase: PHASE2
-
Study Of Advanced Gastrointestinal Malignancies And Other Solid Tumors
NCT00660426 ·Status: COMPLETED ·Phase: PHASE1
-
Gemcitabine Plus Radiation Therapy or Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
NCT00003202 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment
NCT01262482 ·Status: COMPLETED ·Phase: PHASE2
-
Oxaliplatin and Gemcitabine in Treating Patients With Advanced Cancer
NCT00004220 ·Status: COMPLETED ·Phase: PHASE1
-
Docetaxel, Capecitabine, and Cisplatin in Treating Patients With Advanced Solid Tumors
NCT00084734 ·Status: COMPLETED ·Phase: PHASE1
-
Oxaliplatin in Treating Patients With Advanced Cancer Plus Liver Dysfunction
NCT00005077 ·Status: COMPLETED ·Phase: PHASE1